Zongertinib Yields Meaningful Responses in Pretreated HER2-Mutated NSCLC
Zongertinib showed significant efficacy in pretreated NSCLC patients with HER2 TKD mutations, including those with brain metastases, with a 66.7% ORR and 94% tumor shrinkage. The drug was well-tolerated, with no treatment-related deaths and low incidence of dose reductions.
Related Clinical Trials
Reference News
Zongertinib showed significant efficacy in pretreated NSCLC patients with HER2 TKD mutations, including those with brain metastases, with a 66.7% ORR and 94% tumor shrinkage. The drug was well-tolerated, with no treatment-related deaths and low incidence of dose reductions.
Boehringer Ingelheim's zongertinib showed significant objective response rate (ORR) in advanced NSCLC patients with HER2 mutations, with 66.7% ORR and 94% tumor shrinkage. The treatment was well tolerated, with no deaths reported and common AEs being rash and diarrhea.